Investigational drug · Phase 3
TQB2930
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "TQB2930"
First trial start
2023
Apr 13, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQB2930", any sponsor or status.
Conditions studied
As listed on its trial records.
- HER2-positive Advanced Breast Cancer
- Colorectal Cancer
- Metastatic Breast Cancer
- Recurrent Breast Cancer
- Advanced Malignancies
- Advanced Solid Tumor
Approved drugs for the same conditions: Breast cancer · Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "TQB2930" as an intervention, largest first.
- TQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerPivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT07047365 · 416 participants (planned) · Start Jul 25, 2025 · Primary completion Jun 2028
Drug: TQB2930+ chemotherapy; Trastuzumab+ chemotherapy · For: HER2-positive Advanced Breast Cancer
Sites: Bengbu, China; Hefei, China; Beijing, China · 75 sites in all
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT07512583 · 178 participants (planned) · Start May 27, 2026 · Primary completion Mar 2028
Drug: TQB2930 injection+TQB2102 for injection · For: Advanced Solid Tumor
Sites: Beijing, China; Harbin, China; Tianjin, China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06202261 · 154 participants (planned) · Start Apr 13, 2023 · Primary completion Dec 2026
Drug: TQB2930 for injection; Paclitaxel for injection (albumin-bound) and 6 more · For: Metastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignancies
Sites: Chongqing, China; Harbin, China
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT07653685 · 71 participants (planned) · Start Sep 3, 2026 · Primary completion Jun 2027
Drug: TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection; TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets) · For: Colorectal Cancer
Sites: Beijing, China; Chongqing, China; Lanzhou, China · 31 sites in all
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT05380882 · 60 participants (planned) · Start May 2022 · Primary completion Apr 2023
Drug: TQB2930 injection · For: Advanced Cancers
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for HER2-positive Advanced Breast Cancer
- DP303cPhase 34 trials
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · HER2-positive Breast Cancer, Advanced Solid Tumors, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.